FrancophonIA/ELRC3.0 huggingface dataset:
English: Pulmonary function tests
Croatian: Testovi plućne funkcije
English: Results for FEV1, ACQ and AQLQ are shown in Table 5 below for the overall population, and subgroup GINA 4 and 5.
Croatian: Rezultati za FEV1, ACQ i AQLQ prikazani su niže u tablici 5 za ukupnu populaciju i za podskupinu GINA 4 i 5.
English: IL-5 is a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils.
Croatian: IL-5 je ključni citokin odgovoran za diferencijaciju, sazrijevanje, regrutiranje i aktivaciju ljudskih eozinofila.
English: Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases; ATC code: R03DX08
Croatian: Farmakoterapijska skupina: lijekovi za opstruktivne bolesti dišnih puteva, drugi sistemski lijekovi za opstruktivne bolesti dišnih puteva; ATK oznaka: R03DX08
English: Patients with pre-existing helminth infections should be treated before starting reslizumab therapy.
Croatian: Bolesnike s već postojećim infekcijama helmintima treba liječiti prije početka terapije reslizumabom.
English: Your doctor or nurse will watch you closely for signs of a reaction.
Croatian: Liječnik ili medicinska sestra pažljivo će Vas nadzirati zbog znakova reakcije.
English: The volume (in mL) required from the vial(s) should be calculated as follows: 0.3 x patient body weight (in kg).
Croatian: Potrebni volumen (u ml) iz bočice(a) treba izračunati na sljedeći način: 0,3 x tjelesna težina bolesnika (u kg).
English: Sputum eosinophils were measured in a subset of 38 adult patients at the end of therapy.
Croatian: Eozinofili u sputumu bili su izmjereni u podskupini od 38 odraslih bolesnika na kraju terapije.
English: Reslizumab has a volume of distribution of approximately 5 L, suggesting minimal distribution to the extravascular tissues.
Croatian: Reslizumab ima volumen distribucije od približno 5 l, što ukazuje na minimalnu distribuciju u ekstravaskularna tkiva.
English: Particles might be present.
Croatian: Mogu biti prisutne čestice.
English: Elimination Reslizumab clearance is approximately 7 mL/hour.
Croatian: Eliminacija Klirens reslizumaba približno je 7 ml/sat.
English: The highest single dose administered intravenously was reported at 12.1 mg/kg and had no clinical consequences for the patient.
Croatian: Najviša jednokratna doza primijenjena intravenski bila je 12,1 mg/kg i nije imala nikakvih kliničkih posljedica za tog bolesnika.
English: Peak serum concentrations of approximately 80 µg/mL are typically observed at the end of the infusion.
Croatian: Vršne koncentracije u serumu od približno 80 µg/ml obično se opažaju na kraju infuzije.
English: You will be given CINQAERO by a doctor or nurse as an infusion (drip) into a vein.
Croatian: CINQAERO će Vam davati liječnik ili medicinska sestra kao infuziju ("drip", tj. kap po kap) u venu.
English: Your doctor or nurse will watch you closely during and after your infusion for signs of an allergic reaction.
Croatian: Liječnik ili medicinska sestra pažljivo će Vas nadzirati tijekom i nakon infuzije zbog znakova alergijske reakcije.
English: NAb a FEV1=forced expiratory volume in 1 second b NA=not available c The GINA classification is based on the Global Initiative for Asthma (GINA) definition:
Croatian: NAb a FEV1=forsirani ekspiratorni volumen u 1. sekundi b NA=nije dostupno c Klasifikacija GINA temelji se na definiciji Globalne inicijative za astmu (engl.
English: Proportions of patients in GINA steps 4 and 5c
Croatian: Udio bolesnika u GINA koracima 4 i 5c
English: Experience in paediatric patients is limited (see section 5.1).
Croatian: Iskustvo u pedijatrijskih bolesnika je ograničeno (vidjeti dio 5.1).
English: There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of reslizumab in pregnant women.
Croatian: Nema podataka ili su podaci o primjeni reslizumaba u trudnica ograničeni (manje od 300 trudnoća).
English: Proteinaceous particles may be present in the concentrate that appear as translucent to white, amorphous particles, some of which may look fibrous.
Croatian: U koncentratu mogu biti prisutne proteinske čestice koje izgledaju kao prozirne do bijele amorfne čestice, od kojih neke mogu izgledati vlaknasto.
English: This is particularly important: - if you are receiving other medicines which affect your immune system; - if you have recently received a vaccination or if you are likely to need a vaccination.
Croatian: - ako primate druge lijekove koji utječu na imunosni sustav; - ako ste nedavno primili cjepivo ili ćete se vjerojatno trebati cijepiti.
English: In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse effects and given appropriate symptomatic treatment.
Croatian: U slučaju predoziranja, preporučuje se nadzirati bolesnika zbog znakova i simptoma nuspojava te primijeniti odgovarajuće simptomatsko liječenje.
English: Table 3 presents the demographics and baseline characteristics of Studies I, II and III.
Croatian: Tablica 3 prikazuje demografske i početne značajke Ispitivanja I, II i III.
English: These adverse reactions were observed during or within 20 minutes after completion of the infusion.
Croatian: Ove nuspojave bile su opažene tijekom ili unutar 20 minuta nakon završetka infuzije.
English: Efficacy variablea
Croatian: Varijabla djelotvornostia
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 16 hours at 2 °C-8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
Croatian: Ako se ne primijeni odmah, vrijeme i uvjeti čuvanja lijeka prije primjene odgovornost su korisnika i obično ne bi smjeli biti dulji od 16 sati na temperaturi od 2 °C do 8 °C, osim ako se razrjeđivanje nije provelo u kontroliranim i validiranim aseptičkim uvjetima.
English: ** The nominal volume of the vials (10 mL or 2.5 mL for each vial) has to be used.
Croatian: ** Mora se primijeniti nominalni volumen bočica (10 ml ili 2,5 ml za svaku bočicu).
English: There are limited safety data in non-white ethnic populations.
Croatian: Sigurnosni podaci u nebjelačkih populacija su ograničeni.
English: What CINQAERO looks like and contents of the pack
Croatian: Kako CINQAERO izgleda i sadržaj pakiranja
English: The European Medicines Agency has deferred the obligation to submit the results of studies with CINQAERO in one or more subsets of the paediatric population in asthma (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka CINQAERO u jednoj ili više podskupina pedijatrijske populacije za astmu (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: - The active substance is reslizumab.
Croatian: - Djelatna tvar je reslizumab.
English: Improvements were noted in FEV1 at 4 weeks following the first dose of reslizumab.
Croatian: Poboljšanja u FEV1 bila su zabilježena 4 tjedna nakon prve doze reslizumaba.
English: It is recommended that the solution for infusion be administered immediately after preparation.
Croatian: Preporučuje se otopinu za infuziju primijeniti odmah nakon pripreme.
English: These reactions were observed during or within 20 minutes after completion of the reslizumab infusion and were reported as early as the second dose of reslizumab.
Croatian: Te su reakcije bile opažene tijekom ili unutar 20 minuta od završetka infuzije reslizumaba i bile su zabilježene već kod druge doze reslizumaba.
English: Posology CINQAERO is given as intravenous infusion once every four weeks.
Croatian: CINQAERO se daje kao intravenska infuzija jedanput svaka četiri tjedna.
English: Available pharmacodynamic/toxicological data in animals have shown excretion of reslizumab in milk.
Croatian: Dostupni farmakodinamički/toksikološki podaci u životinja pokazuju da se reslizumab/metaboliti izlučuju u mlijeko.
English: CINQAERO blocks interleukin-5 activity and reduces the number of eosinophils in your blood and lungs.
Croatian: CINQUAERO blokira aktivnost interleukina-5 i smanjuje broj eozinofila u krvi i plućima.
English: Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment.
Croatian: Bolesnicima treba savjetovati da potraže savjet liječnika ako im nakon početka liječenja astma i dalje bude nekontrolirana ili se pogorša.
English: A decision to continue the therapy should be made at least annually based on disease severity and level of exacerbation control.
Croatian: O nastavku liječenja odlučuje se najmanje jedanput godišnje na temelju težine bolesti i razine kontrole egzacerbacija.
English: CINQAERO is for intravenous infusion only.
Croatian: CINQAERO se primjenjuje samo intravenskom infuzijom.
English: Adverse reactions are listed below in Table 2 by system organ class and frequency (frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known
Croatian: Nuspojave su navedene niže u tablici 2 prema klasifikaciji organskih sustava i učestalosti (učestalosti su definirane kao: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥ 1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
English: Reslizumab is a humanised monoclonal antibody (IgG4, κ) against the human interleukin-5 (IL-5).
Croatian: Reslizumab je humanizirano monoklonsko protutijelo (IgG4, κ) protiv ljudskog interleukina-5 (IL-5).
English: There are limited data available on the use of reslizumab in patients older than 75 years of age.
Croatian: Dostupni podaci o primjeni reslizumaba u bolesnika starijih od 75 godina su ograničeni.
English: In common with other monoclonal antibodies, reslizumab is believed to be degraded by enzymatic proteolysis into small peptides and amino acids.
Croatian: Kao i druga monoklonska protutijela, smatra se da se reslizumab razgrađuje enzimskom proteolizom na male peptide i aminokiseline.
English: The patient has to be observed over the duration of the infusion and for an appropriate period afterwards.
Croatian: Bolesnika treba nadzirati tijekom trajanja infuzije i odgovarajućeg razdoblja nakon toga.
English: Intravenous use, after dilution only.
Croatian: Primjena u venu, samo nakon razrjeđivanja.
English: It is unlikely that CINQAERO will affect your ability to drive and use machines.
Croatian: Mala je vjerojatnost da će CINQAERO utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
English: Reslizumab is an antibody with a molecular mass of 147 kDaltons and is therefore not expected to be excreted in urine.
Croatian: Reslizumab je protutijelo molekularne mase od 147 kDa pa se, stoga, ne očekuje da će biti izlučen u mokraći.
English: The maximum dose is 3 mg per kg of body weight.
Croatian: Maksimalna doza je 3 mg po kg tjelesne težine.
English: Store in a refrigerator (2 °C-8 °C).
Croatian: Čuvati u hladnjaku (2 °C-8 ºC).
English: Interleukin-5 is a protein your body makes that plays a key role in inflammation in asthma by activating eosinophils.
Croatian: Interleukin-5 je protein koji se stvara u tijelu i ima ključnu ulogu u upali kod astme time što aktivira eozinofile.
English: CINQAERO must not be administered as a bolus injection or as undiluted concentrate.
Croatian: CINQAERO se ne smije primijeniti kao bolus injekcija ili kao nerazrijeđeni koncentrat.
English: The infusion will take about 20 to 50 minutes.
Croatian: Infuzija će trajati oko 20 do
English: Talk to your doctor or nurse before you are given CINQAERO: - if you have a parasitic infection or if you live in an area where parasitic infections are common or if you are travelling to such a region, as this medicine may weaken your body's ability to fight certain types of parasitic infections.
Croatian: - ako imate parazitarnu infekciju ili živite u području gdje su parazitarne infekcije česte ili putujete u takvo područje jer ovaj lijek može oslabiti sposobnost organizma da se obrani od određenih vrsta parazitarnih infekcija.
English: Afterwards, CINQAERO could be used during breast-feeding if appropriate.
Croatian: Nakon tog razdoblja, CINQUAERO se može primjenjivati tijekom dojenja ako se to smatra potrebnim.
English: The malignancies observed in reslizumab-treated patients were diverse in nature and without clustering of any particular tissue type.
Croatian: Zloćudne bolesti opažene u bolesnika liječenih reslizumabom bile su raznolike prirode i nisu zahvaćale neku određenu vrstu tkiva.
English: No direct effect of hepatic function on the pharmacokinetics of reslizumab is expected because antibodies are principally cleared by catabolism.
Croatian: Ne očekuje se nikakav izravni utjecaj funkcije jetre na farmakokinetiku reslizumaba zato što se protutijela u načelu uklanjaju katabolizmom.
English: In humans, during the first few days after birth antibodies may be transferred to the newborns through milk.
Croatian: U ljudi se protutijela mogu prenijeti novorođenčadi putem mlijeka tijekom prvih nekoliko dana nakon rođenja.
English: The recommended dose is 3 mg/kg body weight.
Croatian: Preporučena doza je 3 mg/kg tjelesne težine.
English: Following multiple doses, serum concentrations of reslizumab accumulate approximately 1.5- to 1.9-fold.
Croatian: Nakon višestrukih doza, koncentracija reslizumaba u serumu poveća se približno 1,5-1,9 puta.
English: No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of reslizumab with other medicinal products.
Croatian: Nisu provedena ispitivanja fizikalne ili biokemijske kompatibilnosti da bi se procijenila istovremena primjena reslizumaba s drugim lijekovima.
English: If an anaphylactic reaction occurs, administration of reslizumab should be stopped immediately and appropriate medical treatment should be provided; reslizumab must be discontinued permanently (see section 4.3).
Croatian: Ako nastane anafilaktička reakcija, primjenu reslizumaba treba odmah prekinuti i osigurati odgovarajuće liječenje; primjena reslizumaba mora se trajno prekinuti (vidjeti dio 4.3).
English: Reslizumab should not be used to treat acute asthma exacerbations.
Croatian: Reslizumab se ne smije primjenjivati za liječenje akutnih egzacerbacija astme.
English: No apparent deviation from dose-proportional reslizumab pharmacokinetics was noted over the dose range of 0.3 mg/kg to 3.0 mg/kg.
Croatian: Nije bilo zapaženo vidljivo odstupanje od farmakokinetike proporcionalne dozi za reslizumab u rasponu doza od 0,3 mg/kg do 3,0 mg/kg.
English: Reslizumab binds human IL-5 with picomolar affinity blocking its biological function; consequently survival and activity of eosinophils are reduced.
Croatian: Reslizumab se veže za ljudski IL-5 pikomolarnim afinitetom blokirajući njegovu biološku funkciju; posljedično, preživljenje i aktivnost eozinofila su smanjeni.
English: Do not use this medicine after the expiry date which is stated on the outer carton and label after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnici iza oznaka "Rok valjanosti" i "EXP".
English: The pharmacokinetics of reslizumab was similar in adults (18-65 years of age; n=759) and elderly patients (greater than 65 years of age; n=30).
Croatian: Farmakokinetika reslizumaba bila je slična u odraslih (u dobi od 18 do 65 godina; n=759) i starijih bolesnika (stariji od 65 godina; n=30).
English: The data did not indicate a difference in the safety profile of reslizumab in paediatric patients compared with that in adult patients.
Croatian: Podaci nisu pokazivali razliku u sigurnosnom profilu reslizumaba između pedijatrijskih i odraslih bolesnika.
English: If you stop using CINQAERO
Croatian: Ako prestanete primjenjivati CINQAERO
English: Population pharmacokinetic analyses indicated that the pharmacokinetics of reslizumab is not significantly different between ethnic groups (white, black and Asian).
Croatian: Analize populacijske farmakokinetike pokazale su da nema značajne razlike u farmakokinetici reslizumaba između rasnih skupina (bijela, crna i azijatska).
English: Patients below 35 kg or above 199 kg
Croatian: Bolesnici tjelesne težine manje od 35 kg ili veće od 199 kg
English: Overall, 2,195 subjects received at least one dose of reslizumab.
Croatian: Tablični popis nuspojava Sveukupno je 2195 ispitanika primilo najmanje jednu dozu reslizumaba.
English: Uncommon (may affect up to 1 in 100 people) • Muscle pain (myalgia).
Croatian: Manje često (mogu se javiti u do 1 na 100 osoba) • bol u mišićima (mijalgija).
English: Overall population
Croatian: Ukupna populacija
English: CINQAERO has no or negligible influence on the ability to drive and use machines.
Croatian: CINQAERO ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Table 2: Adverse reactions System organ class
Croatian: Tablica 2: Nuspojave Klasifikacija organskih sustava
English: Reslizumab binds specifically to IL-5 and interferes with IL-5 binding to its cell-surface receptor.
Croatian: Reslizumab se veže specifično za IL-5 i ometa vezanje IL-5 za njegove receptore na površini stanice.
English: Demographics
Croatian: Demografske značajke
English: Due to an overlap in signs and symptoms, it was not possible to distinguish between an anaphylactic reaction, another hypersensitivity reaction and an infusion-related reaction in all cases (see section 4.4).
Croatian: Zbog preklapanja znakova i simptoma nije bilo moguće u svim slučajevima razlikovati anafilaktičku reakciju od neke druge reakcije preosjetljivosti i infuzijske reakcije (vidjeti dio 4.4).
English: Gently invert the bag to mix the solution.
Croatian: Nježno okrenite vrećicu naopako da se otopina promiješa.
English: The primary endpoint was the change from baseline over 16 weeks in FEV1.
Croatian: Primarna mjera ishoda bila je promjena od početne vrijednosti FEV1 tijekom 16 tjedana.
English: Based on the characteristics of reslizumab, drug-drug interactions are not expected.
Croatian: Na temelju značajki reslizumaba, ne očekuju se interakcije s lijekovima.
English: The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Croatian: popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove
English: In a population pharmacokinetic analysis, patients were classified by baseline liver function levels.
Croatian: U analizi populacijske farmakokinetike bolesnici su bili klasificirani prema početnoj razini funkcije jetre.
English: Fertility There are no fertility data in humans.
Croatian: Nema podataka o plodnosti u ljudi.
English: The range of systemic exposures in patients from 12 to less than 18 years of age (n=15) overlapped that in the other groups although the median value was slightly lower than in adult patients (18-65 years of age; n=759) and elderly patients (greater than 65 years of age; n=30).
Croatian: Raspon sistemske izloženosti u bolesnika u dobi od 12 do manje od 18 godina (n=15) preklapao se s onim u drugim skupinama, iako je medijan vrijednosti bio nešto niži nego u odraslih bolesnika (u dobi od 18 do 65 godina; n=759) i starijih bolesnika (stariji od 65 godina; n=30).
English: Table 5: Treatment difference in mean change from baseline for selected secondary efficacy variables - Integrated data (Studies I and II) for the overall population and subgroup GINA 4 and 5
Croatian: Tablica 5: Terapijska razlika u srednjoj vrijednosti promjene od početnih vrijednosti u odabranim sekundarnim varijablama djelotvornosti - integrirani podaci (Ispitivanja I i II) za ukupnu populaciju i podskupinu GINA 4 i 5
English: Mean number of exacerbations in previous year
Croatian: Srednja vrijednost broja egzacerbacija u prethodnoj godini
English: Reslizumab has not been studied in patients concurrently taking immunosuppressant medicinal products other than oral corticosteroids (OCS); therefore, the safety and efficacy profile of reslizumab in these patients is unknown.
Croatian: Reslizumab nije ispitan u bolesnika koji istodobno uzimaju imunosupresivne lijekove koji nisu peroralni kortikosteroidi; stoga profil sigurnosti i djelotvornosti reslizumaba u ovih bolesnika nije poznat.
English: Manifestations included skin or mucosal involvement, dyspnoea, wheezing, gastrointestinal symptoms and chills.
Croatian: Manifestacije su uključivale zahvaćenost kože ili sluznica, dispneju, piskanje pri disanju, gastrointestinalne simptome i zimicu.
English: Improvements were observed as early as 4 weeks following the first dose of reslizumab (AQLQ at 16 weeks) and sustained through week 52.
Croatian: Poboljšanja su bila opažena već u 4. tjednu (AQLQ u 16. tjednu) nakon prve doze reslizumaba i održala su se tijekom 52 tjedna.
English: Results of population pharmacokinetic analysis confirm that concomitant use of either leukotriene antagonists or systemic corticosteroids does not affect the pharmacokinetics of reslizumab (see section 5.2).
Croatian: Rezultati analize populacijske farmakokinetike potvrđuju da istodobna primjena bilo antagonista leukotriena, bilo sistemskih kortikosteroida ne utječe na farmakokinetiku reslizumaba (vidjeti dio 5.2).
English: Inter-individual variability in peak and overall exposure is approximately 20-30%
Croatian: Interindividualna varijabilnost vršne i ukupne izloženosti približno je
English: It is unknown whether reslizumab is excreted in human milk.
Croatian: Nije poznato izlučuje li se reslizumab u majčino mlijeko.
English: CINQAERO is compatible with polyvinylchloride (PVC) or polyolefin (PO) infusion bags.
Croatian: CINQAERO je kompatibilan s infuzijskim vrećicama od polivinilklorida (PVC) ili poliolefina
English: EU/1/16/1125/001 1 vial of 10 mL EU/1/16/1125/002 - 1 vial of 2.5 mL EU/1/16/1125/003 - 2 vials of 10 mL EU/1/16/1125/004 - 2 vials of 2.5 mL
Croatian: EU/1/16/1125/001 1 bočica od 10 ml EU/1/16/1125/002 - 1 bočica od 2,5 ml EU/1/16/1125/003 - 2 bočice od 10 ml EU/1/16/1125/004 - 2 bočice od 2,5 ml
English: ● Periodic safety update reports (PSURs)
Croatian: • Periodička izvješća o neškodljivosti lijeka (PSUR-evi)
English: Most patients had normal liver function tests (n=766, approximately 95%) or mildly increased liver function tests (either, in the first case, total bilirubin above the upper limit of normal [ULN] but less than or equal to 1.5 times the ULN or, in the second case, aspartate aminotransferase greater than the ULN and total bilirubin less than or equal to the ULN; n=35, approximately 4%).
Croatian: Većina bolesnika imala je normalne rezultate testova funkcije jetre (n=766, približno 95 %) ili blago povišene rezultate testova funkcije jetre (bilo, u prvom slučaju, ukupni bilirubin iznad gornje granice normale [GGN], ali ispod ili jednako 1,5 puta GGN ili, u drugom slučaju, aspartat aminotransferaza iznad GGN i ukupni bilirubin ispod ili jednako GGN; n=35, približno 4 %).
English: An updated RMP should be submitted: ● At the request of the European Medicines Agency;
Croatian: • na zahtjev Europske agencije za lijekove;
English: CINQAERO is available in packs containing 1 or 2 vials with 2.5 mL and in packs containing 1 or 2 vials with 10 mL.
Croatian: CINQAERO je dostupan u pakiranjima koja sadrže 1 ili 2 bočice s 2,5 ml i u pakiranjima koja sadrže 1 ili 2 bočice s 10 ml.
English: EU/1/16/1125/001 1 vial of 10 mL EU/1/16/1125/002 1 vial of 2.5 mL EU/1/16/1125/003 2 vials of 10 mL EU/1/16/1125/004 2 vials of 2.5 mL
Croatian: EU/1/16/1125/001 1 bočica od 10 ml EU/1/16/1125/002 1 bočica od 2,5 ml EU/1/16/1125/003 2 bočice od 10 ml EU/1/16/1125/004 2 bočice od 2,5 ml
English: The reduction in blood eosinophil counts by reslizumab in anti-reslizumab antibody-positive patients was not different from patients who were anti-reslizumab antibody-negative.
Croatian: Sniženje broja eozinofila u krvi izazvano reslizumabom u bolesnika s pozitivnim nalazom protutijela protiv reslizumaba nije se razlikovalo od onog u bolesnika s negativnim nalazom protutijela protiv reslizumaba.